-
Is Gilead's Latest Japan Win Good News For Shareholders?
Tuesday, March 31, 2015 - 12:38pm | 554Read More...Gilead Sciences, Inc. (NASDAQ: GILD) announced on March 26 that Japan's Ministry of Health, Labour, and Welfare approved Sovaldi as a hepatitis C treatment. The approval comes a year and a half after the biotech company filed the New Drug Application, making Sovaldi the first Gilead drug...
-
Gilead Shares Tumble On Drug Warning; Baird Says Buy
Monday, March 23, 2015 - 8:33am | 208Read More...Two drugs that account for more than half of Gilead Sciences, Inc.'s (NASDAQ: GILD) sales may also cause abnormally slow heartbeats, according to a warning sent by the company on Friday. Shares of Gilead were lower by more than 3 percent in pre-market trading. According to the warning,...
-
Why This Analyst Thinks Gilead Sciences Will 'Handily' Beat Q4 Expectations
Tuesday, February 3, 2015 - 12:28pm | 277Read More...Gilead Sciences, Inc.'s (NASDAQ: GILD) strong sales of its hepatitis C drug will help it beat expectations when the company posts fourth-quarter earnings later today, an analyst said. "Gilead should beat earnings expectations handily" on strength in sales of its Sovaldi hepatitis...
-
Gilead Sciences' Sovaldi Patent Application Rejected In India
Wednesday, January 14, 2015 - 2:08pm | 140Read More...Gilead Sciences, Inc. (NASDAQ: GILD) patent application for its hepatitis C drug Sovaldi was rejected by the Indian patent office Wednesday, according to Reuters. "The application had been opposed by Indian generic drugmaker Natco Pharma Ltd and New York-based Initiative for Medicines,...
-
UPDATE: Barclays Initiates Coverage On Gilead Sciences, 'Should Remain Ahead Of Its Peers'
Tuesday, January 6, 2015 - 10:08am | 207Read More...Geoffrey Meacham of Barclays initiated coverage of Gilead Sciences, Inc. (NASDAQ: GILD) on Tuesday with an Overweight rating and $125 price target. According to Meacham, Gilead Sciences' will likely see “dramatic growth” in hepatitis C that should drive upside in 2015 and beyond. Specifically, the...
-
Markets Close The Week On Negative Note As Ukraine Worries Mount
Friday, August 15, 2014 - 5:01pm | 2461Read More...U.S. stocks erased early morning gains and finished lower following reports that Ukrainian artillery forces engaged armored vehicles entering Ukraine from Russia. Narayana Kocherlakota, Minneapolis Fed President, stated that labor strength in its current state appears to be far away from the...
-
Gilead Beats Q2 Views On Revenue Growth Lead By Sovaldi Drug
Thursday, July 24, 2014 - 6:50am | 188Read More...Gilead Sciences Inc. (Nasdaq: GILD) beat second-quarter expectations on rapid revenue growth lead by sales of its Sovaldi drug for hepatitis C. The company also boosted its full-year product sales outlook to roughly in line with analysts' consensus. Adjusted income rose to $3.93 billion, or $2.36 a...
-
Biotechs Struggling To Find A Bottom
Tuesday, April 8, 2014 - 10:24am | 971Read More...The great biotechnology sell-off of 2014 began on February 26 and started as big sell-offs often do: quietly. The SPDR S&P Biotechnology exchange-traded fund (NYSE: XBI) peaked at $172.52 and closed at $170.01, off 40 cents from the day before. The next day, the ETF finished at a record...
-
Gilead Sciences Falls Ever-So-Slightly After Q4 Earnings Beat
Tuesday, February 4, 2014 - 5:46pm | 213Read More...Gilead Sciences (NASDAQ: GILD) is down less than one percent in after hours trading after the company announced its fourth quarter results. The company reported a Q4 EPS of $0.55 versus the Street estimate of $0.50. Earnings per share were up 10 percent from the year-ago period. Revenue arrived...
-
Market Wrap For February 4: Investors And Traders Go Bargain Hunting
Tuesday, February 4, 2014 - 5:40pm | 2983Read More...U.S. stocks rose today as investors and traders felt that there were plenty of bargains in the market to be found. "Today is just a bounce. I don't think there is really that much behind it, other than some bargain hunters stepping in," Robert Pavlik, a chief market strategist said to CNBC....
